<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55332">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01909232</url>
  </required_header>
  <id_info>
    <org_study_id>CN-CFS-TRMD-2</org_study_id>
    <nct_id>NCT01909232</nct_id>
  </id_info>
  <brief_title>A Clinical Trial for the Treatment of Depression With Repetitive Transcranial Magnetic Stimulation (rTMS)</brief_title>
  <official_title>A Prospective, Double-Blind, Randomized, Parallel-Group, Sham-Controlled Feasibility Trial of Multi-Coil Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cervel Neurotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cervel Neurotech, Inc.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the Cervel Neurotech rTMS device is safe
      and effective in the treatment of depression in people who do not get better with
      antidepressant medications or cannot take antidepressant medications.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in depression severity</measure>
    <time_frame>Baseline to four weeks (the conclusion of rTMS treatment)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured by the 24-item Hamilton Rating Scale for Depression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in depression severity</measure>
    <time_frame>Baseline to eight weeks (four weeks after the conclusion of rTMS treatment)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured by the 24-item Hamilton Rating Scale for Depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant response</measure>
    <time_frame>Baseline to four weeks (the conclusion of rTMS treatment)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Defined as greater than or equal to 50% decrease in the 24-item Hamilton Rating Scale for Depression score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant response</measure>
    <time_frame>Baseline to eight weeks (four weeks after the conclusion of rTMS treatment)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Defined as greater than or equal to 50% decrease in the 24-item Hamilton Rating Scale for Depression score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission from depression</measure>
    <time_frame>Baseline to four weeks (the conclusion of rTMS treatment)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Defined as 24-item Hamilton Rating Scale for Depression score less than or equal to 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission from depression</measure>
    <time_frame>Baseline to eight weeks (four weeks after the conclusion of rTMS treatment)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Defined as 24-item Hamilton Rating Scale for Depression score less than or equal to 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>Baseline to four weeks (the conclusion of rTMS treatment)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured by the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>Baseline to eight weeks (four weeks after the conclusion of rTMS treatment)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured by the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events and serious adverse events</measure>
    <time_frame>Baseline to eight weeks (four weeks after the conclusion of rTMS treatment)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Depressive Disorder, Major</condition>
  <arm_group>
    <arm_group_label>Active rTMS treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham rTMS treatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Inactive Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator</intervention_name>
    <description>The Cervel Neurotech multi-coil transcranial magnetic stimulator is an investigational repetitive transcranial stimulation (rTMS) device.  In the active group, magnetic power output will be delivered to the subject through the coils.</description>
    <arm_group_label>Active rTMS treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Inactive Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator</intervention_name>
    <description>The Cervel Neurotech multi-coil transcranial magnetic stimulator is an investigational repetitive transcranial stimulation (rTMS) device.  In the inactive group, no magnetic power output will be delivered to the subject through the coils.</description>
    <arm_group_label>Sham rTMS treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current major depressive disorder (MDD)

          -  Resistance or intolerance to antidepressant medication in the current depressive
             episode, or intolerance to antidepressant medication in a past depressive episode

          -  On a stable psychotropic regimen prior to screening and be willing to maintain the
             current regimen and dosing for the duration of the study

          -  Weight less than 350 pounds

        Exclusion Criteria:

          -  Current major depressive disorder episode of more than three years

          -  Seizure disorder

          -  History of brain injury, stroke or active central nervous system disease

          -  Cardiac pacemaker, implanted device (deep brain stimulation) or metal in the brain,
             cervical spinal cord, or upper thoracic spinal cord unless deemed MRI-safe

          -  Active suicidal intent or plan

          -  Other significant psychiatric disorder

          -  Alcohol or substance dependence or abuse

          -  Prior treatment with transcranial magnetic stimulation

          -  Have failed to clinically remit to an adequate trial of electroconvulsive therapy or
             vagus nerve stimulation

          -  If female, pregnant or lactating or planning to become pregnant within the next three
             months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beth Stannard, BS, CCRP, CCRC</last_name>
    <role>Study Director</role>
    <affiliation>Cervel Neurotech</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheppard-Pratt Health System</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21285</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Center for Health Research</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Butler Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRI Lifetree</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.TheDepressionTrial.com?prsid=53&amp;praid=1&amp;prtid=1</url>
    <description>Study Website</description>
  </link>
  <link>
    <url>http://www.cervel.com</url>
    <description>Sponsor Website</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>July 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Depressive Disorder</keyword>
  <keyword>Major depression</keyword>
  <keyword>Major depressive disorder</keyword>
  <keyword>MDD</keyword>
  <keyword>Treatment resistant depression</keyword>
  <keyword>Treatment intolerant depression</keyword>
  <keyword>TRMD</keyword>
  <keyword>TIMD</keyword>
  <keyword>Transcranial Magnetic Stimulation</keyword>
  <keyword>TMS</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
